Organization (Industry)
DYNAVAX TECHNOLOGIES CORPORATION
ClinicalTrials.gov lists DYNAVAX TECHNOLOGIES CORPORATION as lead sponsor of 25 trials. It has 12 active development programs and 8 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers DYNAVAX TECHNOLOGIES CORPORATION: 25 lead-sponsored trials and 3 legal-entity registrations.
Disease areas (24)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Hepatitis B | 15 |
| Kidney Failure, Chronic | 5 |
| Renal Insufficiency, Chronic | 5 |
| Vaccine-Preventable Diseases | 3 |
| HIV Infections | 2 |
Showing 5 of 24 disease areas.
Trials by start year as sponsor or collaborator (16)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 3 |
| 2019 | 2 |
| 2017 | 1 |
| 2015 | 1 |
| 2014 | 2 |
| 2013 | 1 |
Showing 10 of 16 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (12)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| HEPLISAV-B | Hepatitis B | Phase 3 | 3 |
| HEPLISAV-B | Kidney Failure, Chronic | Phase 3 | 2 |
| HEPLISAV-B | Renal Insufficiency, Chronic | Phase 3 | 2 |
| rF1V vaccine | Vaccine-Preventable Diseases | Phase 2 | 1 |
| rF1V-1018 | Plague | Phase 2 | 1 |
Showing 5 of 12 active programs.
Approved assets (8)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| HEPLISAV-B | 3 |
| FENDRIX | 1 |
| Histamine | 2 |
| SHINGRIX | 2 |
| PEMBROLIZUMAB | 1 |
Showing 5 of 8 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 80% hit target (n=5) | 20% on time (n=5) |
Journals published in (8)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Vaccine | 6 |
| Cancer cytopathology | 1 |
| Cancer discovery | 1 |
| Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology | 1 |
| Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 1 |
Showing 5 of 8 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 65 | 7 | 2025-08-05 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 1 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Dynavax Technologies Corporation | Emeryville, US | FDA |
Organization relationships (11)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 4 |
| Merck & Co., Inc., Rahway, NJ, USA (United States) | Co sponsors trial with | 1 |
| Dana-Farber Cancer Institute | Co sponsors trial with | 1 |
| University of Rochester | Co sponsors trial with | 1 |
| University of California System | Co sponsors trial with | 1 |
Showing 5 of 11 relationships.
Latest dated events (96)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-09-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-08-05 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-07-22 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-05-13 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-06-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 96 events.
Biomarker capability evidence (74)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALK | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| EGFR | Trial sponsor | Named in trial inclusion criteria |
| F2 | Trial sponsor | Named in trial inclusion criteria |
| F2 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 74 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.